The Future
is Synthetic

Nucleic acids for next-generation therapeutics and vaccines


Synthetic DNA, a transformative alternative

Providing you with a strategic advantage for vaccine and therapeutic development, eliminating bottlenecks and accelerating innovation in genetic medicine.

2 overlapping squares with an arrow in white
Clock icon
Shield with tick icon
water drop icon in white

4x faster

Robust scalability

vs pDNA production, as little
as 8 weeks

From discovery
to clinic

Purity

Enhanced safety

Efficient by
design

No bacterial sequences

Applications

With state-of-the-art, application-specific synthetic DNA solutions 4basebio have addressed the diverse requirements for therapeutic and vaccine development. You’ll reach proof of concept and subsequent clinical milestones faster and more efficiently while ensuring the highest safety and quality standards for your genetic medicines.

Improve your mRNA yields and simplify production workflows for mRNA vaccines and therapeutics.

Mitigate packaging of exogenous sequences, while achieving equivalent viral titers using less DNA input material.

Increase gene editing efficiency with dsDNA and ssDNA templates across a wide range of gene editing applications.

Latest news from 4basebio


07 JUL 2025 / PRESS RELEASE

Influenza Research Consortium announces £1.2 million (C$2.2 million) in funding for the development of a novel broad-spectrum vaccine

4basebio PLC, ConserV Bioscience Limited, Pegasus Biotech, the University of Leicester, and the National Research Council of Canada (NRC) announce that the UK and Canadian governments are providing up to a combined £1.2 million (C$2.2 million) in funding to develop and manufacture a broadly protective influenza vaccine. This project is supported through the Canada-UK 2024-25 collaborative industrial R&D call for proposals on enabling technologies and innovations for biomanufacturing of biologics and advanced therapeutics.

READ HERE


01 JUL 2025 / PRESS RELEASE

4basebio introduces new branding to reflect next phase of growth enabling development of advanced genetic therapies

Today we introduced a refined visual system, including a modernised logo, refreshed colour palette, and a suite of new imagery. The Company’s redesigned website provides a more intuitive access point for partners and customers, providing detailed information and support for 4basebio’s expanding capabilities across synthetic DNA, mRNA, gene editing, and plasmid-free manufacturing.

READ HERE


06 MAY 2025 / BLOG

No bacteria, no bottlenecks: The future of DNA IVT templates is synthetic

The remarkable success of mRNA therapies and vaccines, highlighted during the COVID-19 pandemic, is revolutionizing modern medicine. Central to the production of these mRNA-based interventions is the DNA template used in in vitro transcription (IVT) reactions. Traditionally, plasmid DNA (pDNA) has been the foundation for such therapies.

READ MORE


Accelerate your timelines with GMP synthetic DNA

With the right partner and a clear strategy, companies can unlock synthetic DNA’s benefits, de-risking manufacturing, reducing lead times and accelerating development milestones, while maintaining programme continuity and momentum.
— HelixNano